Inhibition of Hepatitis B Virus Replication by Helper Dependent Adenoviral Vectors Expressing Artificial Anti-HBV Pri-miRs from a Liver-Specific Promoter

Research on applying RNA interference (RNAi) to counter HBV replication has led to identification of potential therapeutic sequences. However, before clinical application liver-specific expression and efficient delivery of these sequences remain an important objective. We recently reported short-term inhibition of HBV replication in vivo by using helper dependent adenoviral vectors (HD Ads) expressing anti-HBV sequences from a constitutively active cytomegalovirus (CMV) promoter. To develop the use of liver-specific transcription regulatory elements we investigated the utility of the murine transthyretin (MTTR) promoter for expression of anti-HBV primary microRNAs (pri-miRs). HD Ads containing MTTR promoter effected superior expression of anti-HBV pri-miRs in mice compared to HD Ads containing the CMV promoter. MTTR-containing HD Ads resulted in HBV replication knockdown of up to 94% in mice. HD Ads expressing trimeric anti-HBV pri-miRs silenced HBV replication for 5 weeks. We previously showed that the product of the codelivered lacZ gene induces an immune response, and the duration of HBV silencing in vivo is likely to be attenuated by this effect. Nevertheless, expression of anti-HBV pri-miRs from MTTR promoter is well suited to countering HBV replication and development of HD Ads through attenuation of their immunostimulatory effects should advance their clinical utility.

[1]  A. Ely,et al.  Inhibition of HBV replication in vivo using helper-dependent adenovirus vectors to deliver antiviral RNA interference expression cassettes , 2014, Antiviral therapy.

[2]  A. Masoudi-Nejad,et al.  Human RNAi pathway: crosstalk with organelles and cells , 2014, Functional & Integrative Genomics.

[3]  K. Tsuneyama,et al.  Studies of efficacy and liver toxicity related to adeno-associated virus-mediated RNA interference. , 2013, Human gene therapy.

[4]  Wenge Li,et al.  Comparison of prednisolone and lamivudine combined therapy with prednisolone monotherapy on carriers of hepatitis B virus with IgA nephropathy: a prospective cohort study , 2013, International Urology and Nephrology.

[5]  A. Ely,et al.  Efficient silencing of hepatitis B virus by helper-dependent adenovirus vector-mediated delivery of artificial antiviral primary micro RNAs. , 2012, MicroRNA.

[6]  Joshua T. Schiffer,et al.  Targeted DNA Mutagenesis for the Cure of Chronic Viral Infections , 2012, Journal of Virology.

[7]  T. Flotte,et al.  Sustained miRNA-mediated Knockdown of Mutant AAT With Simultaneous Augmentation of Wild-type AAT Has Minimal Effect on Global Liver miRNA Profiles , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  A. Ely,et al.  Countering hepatitis B virus infection using RNAi: how far are we from the clinic? , 2011, Reviews in medical virology.

[9]  Beverly L. Davidson,et al.  Current prospects for RNA interference-based therapies , 2011, Nature Reviews Genetics.

[10]  P. Arbuthnot,et al.  Therapeutic potential of adenoviral vectors for delivery of expressed RNAi activators , 2010, Expert opinion on drug delivery.

[11]  Theresa A. Storm,et al.  Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. , 2010, The Journal of clinical investigation.

[12]  A. Ely,et al.  Inhibition of hepatitis B virus replication with linear DNA sequences expressing antiviral micro-RNA shuttles. , 2009, Biochemical and biophysical research communications.

[13]  N. Brunetti‐Pierri,et al.  Progress towards liver and lung-directed gene therapy with helper-dependent adenoviral vectors. , 2009, Current Gene Therapy.

[14]  A. Ely,et al.  Efficient silencing of gene expression with modular trimeric Pol II expression cassettes comprising microRNA shuttles , 2009, Nucleic acids research.

[15]  Yeup Yoon,et al.  Optimization of linear double-stranded RNA for the production of multiple siRNAs targeting hepatitis C virus. , 2009, RNA.

[16]  J. Prieto,et al.  Treatment of Chronic Viral Hepatitis in Woodchucks by Prolonged Intrahepatic Expression of Interleukin-12 , 2008, Journal of Virology.

[17]  M. Kay,et al.  Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  P. Marion,et al.  Efficient inhibition of hepatitis B virus replication in vivo, using polyethylene glycol-modified adenovirus vectors. , 2008 .

[19]  P. Marion,et al.  Exploring gene‐deleted adenoviral vectors for delivery of short hairpin RNAs and reduction of hepatitis B virus infection in mice , 2008, The journal of gene medicine.

[20]  A. Ely,et al.  Expressed anti-HBV primary microRNA shuttles inhibit viral replication efficiently in vitro and in vivo. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  Theresa A. Storm,et al.  The host response to adenovirus, helper-dependent adenovirus, and adeno-associated virus in mouse liver. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  Brian L. Gilmore,et al.  Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi , 2008, Proceedings of the National Academy of Sciences.

[23]  C. Napoli,et al.  Adenovirus Serotype 5 Hexon Mediates Liver Gene Transfer , 2008, Cell.

[24]  R. Sun,et al.  Therapeutic RNA silencing of Cys‐X3‐Cys chemokine ligand 1 gene prevents mice from adenovirus vector‐induced acute liver injury , 2007, Hepatology.

[25]  Theresa A. Storm,et al.  Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways , 2006, Nature.

[26]  P. Marion,et al.  Effective inhibition of HBV replication in vivo by anti-HBx short hairpin RNAs. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[27]  G. Ciliberto,et al.  Regulated and Liver-Specific Tamarin Alpha Interferon Gene Delivery by a Helper-Dependent Adenoviral Vector , 2005, Journal of Virology.

[28]  D. Muruve,et al.  The induction of inflammation by adenovirus vectors used for gene therapy. , 2005, Frontiers in bioscience : a journal and virtual library.

[29]  A. Ely,et al.  Exploiting the RNA interference pathway to counter hepatitis B virus replication , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[30]  D. Muruve,et al.  The innate immune response to adenovirus vectors. , 2004, Human gene therapy.

[31]  B. Pützer,et al.  Helper-Dependent Adenoviral Vector-Mediated Delivery of Woodchuck-Specific Genes for Alpha Interferon (IFN-α) and IFN-γ: IFN-α but Not IFN-γ Reduces Woodchuck Hepatitis Virus Replication in Chronic Infection In Vivo , 2004, Journal of Virology.

[32]  F. González‐Huix,et al.  Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis , 2004, Gut.

[33]  G. Maelandsmo,et al.  Helper-Dependent Adenovirus Vectors Elicit Intact Innate but Attenuated Adaptive Host Immune Responses In Vivo , 2004, Journal of Virology.

[34]  M. Taniguchi,et al.  The NKT cell system: bridging innate and acquired immunity , 2003, Nature Immunology.

[35]  D. Palmer,et al.  Improved system for helper-dependent adenoviral vector production. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  M. Winters,et al.  A transgenic mouse lineage useful for testing antivirals targeting hepatitis B virus , 2003 .

[37]  D. Harrison,et al.  Adenovirus-mediated Cre deletion of floxed sequences in primary mouse cells is an efficient alternative for studies of gene deletion. , 2001, Nucleic acids research.

[38]  J. Wilson,et al.  Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[39]  F. Chisari,et al.  Noncytolytic control of viral infections by the innate and adaptive immune response. , 2001, Annual review of immunology.

[40]  G. Ciliberto,et al.  Liver-Specific Alpha 2 Interferon Gene Expression Results in Protection from Induced Hepatitis , 2000, Journal of virology.

[41]  P. Arbuthnot,et al.  In situ demonstration of inhibitory effects of hammerhead ribozymes that are targeted to the hepatitis Bx sequence in cultured cells. , 2000, Biochemical and biophysical research communications.

[42]  V. Sandig,et al.  Reactivation of the Previously Silenced Cytomegalovirus Major Immediate-Early Promoter in the Mouse Liver: Involvement of NFκB , 1998, Journal of Virology.

[43]  H. Volk,et al.  Inactivation of the very strong HCMV immediate early promoter by DNA CpG methylation in vitro. , 1996, Biological chemistry Hoppe-Seyler.

[44]  M. Nassal.  The arginine-rich domain of the hepatitis B virus core protein is required for pregenome encapsidation and productive viral positive-strand DNA synthesis but not for virus assembly , 1992, Journal of virology.

[45]  R. Costa,et al.  Site-directed mutagenesis of hepatocyte nuclear factor (HNF) binding sites in the mouse transthyretin (TTR) promoter reveal synergistic interactions with its enhancer region. , 1991, Nucleic acids research.